Form 4: Arrowhead Pharmaceuticals Executive Tracie Oliver Sells Shares to Cover Tax Obligations

Tracie Oliver, Chief Commercial Officer of Arrowhead Pharmaceuticals, sold shares of common stock on July 2, 2024, to satisfy tax withholding obligations related to restricted stock units.

Summary

• On July 2, 2024, Tracie Oliver, the Chief Commercial Officer of Arrowhead Pharmaceuticals, sold 9,394 shares of common stock.
• The sale was executed at a price of $25.28 per share.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan.
• The sale was a partial disposition of Restricted Stock Units (RSUs) to cover tax withholding obligations.
• Following the transaction, Oliver still beneficially owns 127,107 shares, including shares underlying previously reported Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale is for tax purposes and doesn't necessarily reflect a negative outlook on the company.

Industry Context

Sales by company executives are a normal part of corporate governance. Sales to cover tax obligations are common when executives are granted stock or options as part of their compensation.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the stated reason (tax obligations) mitigates potential concerns.

Key Dates